Philip Tipton, MD, Mayo Clinic, Jacksonville, FL, discusses questions and prospects regarding anti-amyloid therapies. There are two essential questions: if the statistical significance of the treatment is translated to clinical meaningfulness, and the adverse events, such as amyloid-related imaging abnormalities (ARIA) and infusion reactions. ARIA can manifest as ARIA-e or –h, and both can be a significant concern. Trials investigating anti-amyloid therapies should account for the potential benefit in clinical use against the possible adverse effects of treatment before moving forward with the investigation. Additionally, there have been reported gender and racial differences in some clinical data regarding lecanemab, which need to be clarified before making decisions moving forward. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
